AD

Array Digital Infrastructure, Inc.
NYSECOMMUNICATION SERVICESTELECOM SERVICES

Key Statistics

Market Cap
$3.06B
P/E Ratio
4.70
EPS
$7.53
Beta
0.28
52W High
$46.04
52W Low
$28.86
50-Day MA
$37.46
200-Day MA
$46.60
Dividend Yield
30.60%
Profit Margin
250.80%
Forward P/E
7.79
PEG Ratio
1.80

About Array Digital Infrastructure, Inc.

Array Digital Infrastructure, Inc. provides wireless telecommunications services in the United States. The company is headquartered in Chicago, Illinois.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$213.53M
Gross Profit (TTM)$124.63M
EBITDA$53.07M
Operating Margin-12.50%
Return on Equity22.70%
Return on Assets0.02%
Revenue/Share (TTM)$2.47
Book Value$14.63
Price-to-Book2.46
Price-to-Sales (TTM)14.32
EV/Revenue18.23
EV/EBITDA4.38
Quarterly Earnings Growth (YoY)1051.00%
Quarterly Revenue Growth (YoY)89.50%
Shares Outstanding$53.47M
Float$15.56M
% Insiders71.55%
% Institutions35.78%

Historical Volatility

HV 10-Day
18.57%
HV 20-Day
19.69%
HV 30-Day
18.16%
HV 60-Day
25.05%
HV Rank
0.8%

Volatility is currently expanding

Analyst Ratings

Consensus ($46.33 target)
1
Strong Buy
1
Buy
2
Hold

Latest News

Array Digital Infrastructure Q2 Earnings Call Highlights

TDS reported second-quarter progress in its fiber expansion and tower infrastructure operations, while updating 2026 guidance for both TDS Telecom and Array Digital Infrastructure NYSE: AD. Management also said it would not provide further updates or take questions regarding TDS's pending proposal to acquire Array shares it does not already own.

MarketBeat8/12/2026Positive
Array reports second quarter 2026 results

Array updates 2026 guidance CHICAGO, Aug. 7, 2026 /PRNewswire/ -- As previously announced, Array will hold a teleconference on August 7, 2026, at 9:00 a.m. CT. Listen to the call live via the Events & Presentations page of investors.arrayinc.com.

PRNewsWire8/7/2026Neutral
LAPIX Therapeutics Appoints Nimbus CEO Abbas Kazimi to Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--LAPIX Therapeutics has appointed Abbas Kazimi, Chief Executive Officer of Nimbus Therapeutics, to its Board of Directors as the Company advances its TIM 3/4 agonist program through Phase 1b clinical trials in rheumatoid arthritis (RA) and atopic dermatitis (AD). Kazimi brings more than two decades of biotechnology leadership experience spanning company building, corporate strategy, financing, and drug development. As CEO of Nimbus Therapeutics, he has overseen.

Business Wire7/27/2026Neutral
AD Mortgage Survey Finds Growing Demand for Non-QM Lending Among Brokers

FORT LAUDERDALE, Fla., June 23, 2026 (GLOBE NEWSWIRE) -- AD Mortgage , a leading wholesale lender in the United States, today released findings from its latest broker survey,  Non-QM Fuels Mortgage Industry in 2026  revealing strong momentum for Non-QM lending across the mortgage industry.

GlobeNewsWire6/23/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AD and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More COMMUNICATION SERVICES Stocks

Data last updated: 8/18/2026